Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basimglurant in trigeminal neuralgia
NCT05217628Phase 3Active, not recruiting
- Sponsor
- Noema Pharma
- Start
- Jan 2022
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of basimglurant in trigeminal neuralgia (TN), sponsored by Noema Pharma. Started Jan 2022; status: active, not recruiting.
02
Drugs
basimglurant
03
Conditions
trigeminal neuralgia (TN)
Beyond the preview
Go deeper on NCT05217628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05217628.